CN110938071A

CN110938071A - Heteroaromatic compound with kinase inhibition activity

Info

Publication number: CN110938071A
Application number: CN201811110497.7A
Authority: CN
Inventors: 江磊; 冯志勇; 刘胜洋; 毛旭东; 尚珂; 寿建勇; 吴淡宜; 徐圆; 张建华; 郑明伟
Original assignee: Shanghai Yi Connaught Pharmaceutical Co Ltd
Current assignee: Shanghai Yi Connaught Pharmaceutical Co Ltd
Priority date: 2018-09-21
Filing date: 2018-09-21
Publication date: 2020-03-31

Abstract

The invention provides a JAK kinase inhibitor and preparation and application thereof. Specifically, the invention provides a compound shown as a formula I, wherein the definition of each group is described in the specification. The compound has excellent JAK inhibitory activity, so that the compound can be used for preparing a pharmaceutical composition for treating cancers and other diseases related to JAK activity.

Description

Heteroaromatic compound with kinase inhibition activity

Technical Field

The invention relates to the field of small molecule drugs, in particular to a kinase inhibitor and preparation and application thereof.

Background

Janus kinases (JAKs) are cytoplasmic tyrosine protein kinases responsible for transducing many inflammation-associated cytokine signals from cytokine membrane receptors to STAT transcription factors. Four family members are generally considered to be comprised: JAK1, JAK2, JAK3 and TYK 2. When a particular cytokine binds to its receptor, JAK family members coupled to that receptor undergo autophosphorylation and/or transphosphorylation on each other, followed by phosphorylation of the substrate protein STATs, which migrate to the nucleus to regulate transcription, thereby transmitting extracellular signals into the cell. The JAK-STAT intracellular signal transduction pathway is a signal transduction pathway related to immune and inflammatory reactions in a body. JAK-STAT mediates important signaling of interferons IFN, most interleukins IL, and a variety of cytokines and endocrine factors, such as EPO, TP0, GH, and GM-CSF.

JAK/STAT signaling abnormalities are associated with a number of diseases, and are involved in immune inflammation-related diseases such as organ transplant rejection, multiple sclerosis, rheumatoid arthritis, type I diabetes, lupus, psoriasis, asthma, food allergies, atopic dermatitis and rhinitis, skin rash, and the like; it has also been reported to be closely related to the development of solid and hematologic malignancies as well as myeloproliferative disorders including lung cancer, breast cancer, chronic idiopathic myelofibrosis, polycythemia, essential thrombocythemia, etc.

JAK kinase inhibitors provide a new approach for the treatment of JAK-associated diseases such as inflammatory diseases, autoimmune diseases, myeloproliferative diseases, and cancer by blocking JAK-associated signal transduction. For example, JAK kinase inhibitors are currently approved by the FDA for the treatment of diseases such as rheumatoid arthritis. However, patients who take these drugs suffer from adverse effects such as anemia, possible serious infections and the risk of heart failure. Therefore, it is desirable to develop inhibitors with better JAK selectivity or pharmacokinetic properties or better safety to effectively treat JAK-STAT related diseases.

In view of the above, there is an urgent need in the art for the development of novel selective inhibitors of JAK.

Disclosure of Invention

The invention aims to provide a JAK kinase inhibitor and preparation and application thereof.

In a first aspect of the present invention, there is provided a compound of formula I:

wherein,

X¹、X²、X³and X⁴Each independently is CH or N; and X¹、X²、X³And X⁴At least one of which is N;

the ring is selected from the group consisting of: a 6-10 membered aromatic ring, or a 5-10 membered heteroaromatic ring;

R¹independently selected from the group consisting of: H. substituted or unsubstituted C1-C6 alkyl;

R²、R³each independently selected from the group consisting of: H. halogen, CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, -S (═ O)₂R₇；

R⁴、R⁵Each independently selected from the group consisting of: H. halogen, CN, substituted or unsubstituted C1-C6 alkyl;

R⁶selected from the group consisting of: H. substituted or unsubstituted C1-C6 alkyl, R⁷-C(＝O)-、R⁸-S(＝O)₂-、R⁹R¹⁰N-C(＝O)-、R¹¹R¹²N-S(＝O)₂-, a substituted or unsubstituted 5-to 12-membered heterocyclic group having 1 to 3 hetero atoms selected from the group consisting of N, S and O (including monocyclic, spiro, and the like),Bridged or fused rings);

R⁷、R⁸、R⁹、R¹⁰、R¹¹、R¹²each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 5-12 membered heterocyclyl having 1-3 heteroatoms selected from the group consisting of N, S and O;

unless otherwise specified, "substituted" means substituted with one or more (e.g., 2,3, 4, etc.) substituents selected from the group consisting of: halogen, C1-C6 alkoxy, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, halogenated C3-C8 cycloalkyl, methylsulfonyl, oxo (═ O), -CN, hydroxy, -NH₂C1-C6 amino, carboxyl, C1-C6 amido (-C (═ O) -n (rc)₂or-NH-C (═ O) (Rc), Rc being H or C1-C5 alkyl), or a substituted or unsubstituted group selected from: C1-C6 alkyl, C6-C10 aryl, 5-to 10-membered heteroaryl having 1-3 heteroatoms selected from N, S and O, - (CH)₂) -C6-C10 aryl, - (CH)₂) - (5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O), - (5-10 membered heteroarylene having 1-3 heteroatoms selected from N, S and O) - (C1-C6 alkyl), substituted or unsubstituted 5-12 membered heterocyclic group (including monocyclic, spiro, bridged or fused ring) having 1-3 heteroatoms selected from N, S and O, and the substituent is selected from the group consisting of: halogen, C1-C6 alkyl, C1-C6 alkylene-OH, C1-C6 alkoxy, oxo, -CN, -OH, C6-C10 aryl, 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, S and O;

and in the compound of the formula I, each chiral center is in an R configuration or an S configuration.

In another preferred embodiment, the 5-12 membered heteroaromatic ring is selected from the group consisting of: a pyridine ring, a pyrimidine ring, a pyridazine ring, a tetrazine ring, a triazine ring, a pyrrole ring, a thiophene ring, a furan ring, a tetraazozole ring, a triazazole ring, an imidazole ring, a thiazole ring, an oxazole ring, a pyrazole ring, an isothiazole ring, an isoxazole ring, an oxadiazole ring, and a thiadiazole ring.

In another preferred embodiment, the compound of formula I has a structure as shown in formula Ia or formula Ib:

wherein R is₇Selected from the group consisting of: H. substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C8 cycloalkyl.

In another preferred embodiment, the compound of formula I has a structure selected from the group consisting of:

in another preferred embodiment, the compound has the structure shown in formula II below:

wherein,

R^6aselected from the group consisting of: H. substituted or unsubstituted C1-C6 alkyl;

R^7a、R^8a、R^9a、R^10aselected from the group consisting of: hydrogen, substituted or unsubstituted C1-C6 alkyl;

R^11aselected from the group consisting of: hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C1-C6 amine;

wherein said substitution means that one or more hydrogen atoms on the group are substituted with a substituent selected from the group consisting of: halogen, hydroxy, substituted or unsubstituted C1-C6 alkoxy.

In another preferred embodiment, R is^7a、R^8a、R^9a、R^10aSelected from the group consisting of: hydrogen, methyl;

said R^11aSelected from the group consisting of: methyl, ethyl, hydroxyethyl, methoxyethyl, halogenated C1-C6 alkyl.

In another preferred embodiment, R is⁴Is H, and said R⁵Is methyl.

In another preferred embodiment, R¹Selected from the group consisting of: methyl and ethyl.

In another preferred embodiment, R²Selected from the group consisting of: methyl, ethyl, methoxy, ethoxy.

In another preferred embodiment, R³、R⁴Each independently hydrogen.

In another preferred embodiment, R⁵Selected from the group consisting of: hydrogen, methyl, chlorine, fluorine, bromine, trifluoromethyl.

In another preferred embodiment, R⁶Selected from the group consisting of: 3,3, 3-trifluoro-2-hydroxypropyl, 2- (4-methylpiperazin-1-yl) butanoyl.

In another preferred embodiment, the compound of formula I is selected from the group consisting of:

in a second aspect of the invention, there is provided a pharmaceutical composition comprising (1) a compound according to the first aspect of the invention or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof; (2) a pharmaceutically acceptable carrier.

In another preferred embodiment, the pharmaceutical composition is an injection, a capsule, a tablet, a pill, a powder or a granule.

In another preferred embodiment, the pharmaceutical composition further comprises an additional therapeutic agent, wherein the additional therapeutic agent is a drug for cancer, cardiovascular disease, inflammation, immune disease, myeloproliferative disease, viral disease, metabolic disease, or organ transplantation.

More preferably, the additional therapeutic agents include (but are not limited to): 5-fluorouracil, avastin^TM(avastin, bevacizumab), bexarotene (bexarotene), bortezomib (bortezomib), calcitriol (calceinol), canertinib (canertinib), capecitabine (capecitabine), carboplatin (carboplatin), celecoxib (celecoxib), cetuximab (cetuximab), cisplatin (cisplatin), dasatinib (dasatinib), digoxin (digoxin), enzarin (enzastaurin), Erlotinib (Erlotinib), etoposide (etoposide), everolimus (evololimus), fulvestrant (fulvestrant), gefitinib (gefitinib), 2-difluorodeoxycytidine (gemcitabine), genistein (genistin), imatinib (imatinib), rituximab (rituximab), paclitaxel (paclitaxel), paclitaxel (bleomycin), paclitaxel (oxaliplatin), paclitaxel (paclitaxel), paclitaxel (oxaliplatin), paclitaxel (paclitaxel), paclitaxel (oxaliplatin (paclitaxel), paclitaxel (oxaliplatin (paclitaxel), paclitaxel (oxaliplatin (paclitaxel), paclitaxel (paclitaxel), paclitaxel (interferon (paclitaxel), paclitaxel (interferon (,

E. Satraplatin (satraplatin), sirolimus (sirolimus), sunitinib (sutent), sulindac (sulindac), taxotere (taxotere), temozolomide (temodar, temomolomide), Torisel (Torisel), temsirolimus (temiriolimus), tipifarnib (tipifarnib), trastuzumab (trastuzumab), valproic acid (valproic acid), vinflunine (vinflunine), Volociximab, Vorinostat, Sorafenib, ambrisentan (ambrisentan), CD40 and/or CD154 specific antibodies, fusion proteins, NF-kB inhibitors, non-specific antibodies, fusion proteins, NF-kB inhibitors, and the likeSteroidal anti-inflammatory drugs, β -agonists such as salmeterol and the like, coagulation factor FXa inhibitors (such as rivaroxaban and the like), anti-TNF antibodies, prostaglandin drugs, or montelukast (montelukast).

In a third aspect of the present invention, there is provided a use of a compound according to the first aspect of the present invention or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to the second aspect of the present invention for the preparation of a pharmaceutical composition for the prevention and/or treatment of a disease associated with an activity or an expression amount of a JAK kinase.

In another preferred embodiment, the disease is selected from the group consisting of: cancer, cardiovascular disease, inflammation, immunological disease, myeloproliferative disease, viral disease, metabolic disease, or organ transplantation.

In another preferred embodiment, the cancer includes (but is not limited to): non-small cell lung cancer, uterine cancer, rectal cancer, colon cancer, brain cancer, head cancer, neck cancer, bladder cancer, prostate cancer, breast cancer, kidney cancer, leukemia, liver cancer, stomach cancer, thyroid cancer, nasopharyngeal cancer, or pancreatic cancer.

In another preferred embodiment, the myeloproliferative disease includes (but is not limited to): essential Thrombocythemia (ET), Idiopathic Myelofibrosis (IMF), Chronic Myelogenous Leukemia (CML), primary myelofibrosis, Chronic Neutrophilic Leukemia (CNL), or Polycythemia Vera (PV).

In another preferred embodiment, the immune or inflammatory disease includes (but is not limited to): rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gout, asthma, bronchitis, rhinitis, chronic obstructive pulmonary disease, pulmonary fibrosis, and cystic fibrosis.

In another preferred embodiment, the metabolic disease includes (but is not limited to): type 2 diabetes, type 1 diabetes, diabetic complications (such as diabetic nephropathy, diabetic retinopathy, non-alcoholic steatohepatitis, liver fibrosis, insulin resistance, obesity).

In a fourth aspect of the invention, there is provided a JAK inhibitor comprising a compound according to the first aspect of the invention, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

In another preferred embodiment, the JAK inhibitor selectively inhibits one or more JAK kinases selected from the group consisting of: JAK1, JAK2, JAK3 or Tyk 2.

In another preferred embodiment, the JAK inhibitor is a JAK1 inhibitor.

It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. Not to be reiterated herein, but to the extent of space.

Detailed Description

The present inventors have conducted long and intensive studies to design and synthesize a novel class of JAK kinase inhibitors. On this basis, the inventors have completed the present invention.

Term(s) for

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

As used herein, the term "about" when used in reference to a specifically recited value means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes 99 and 101 and all values in between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

As used herein, the term "comprising" or "includes" can be open, semi-closed, and closed. In other words, the term also includes "consisting essentially of …," or "consisting of ….

Definition of

As used herein, the term "alkyl" includes straight or branched chain alkyl groups. E.g. C₁-C₈Alkyl represents a straight or branched chain alkyl group having 1 to 8 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, and the like.

As used herein, the term "alkenyl" includes straight or branched chain alkenyl groups. E.g. C₂-C₆Alkenyl means a straight or branched alkenyl group having 2 to 6 carbon atoms, such as vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, or the like.

As used herein, the term "alkynyl" includes straight or branched chain alkynyl groups. E.g. C₂-C₆Alkynyl means straight or branched chain alkynyl having 2 to 6 carbon atoms, such as ethynyl, propynyl, butynyl, or the like.

As used herein, the term "C₃-C₈Cycloalkyl "refers to cycloalkyl groups having 3 to 8 carbon atoms. It may be a single ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or the like. It may also be in the form of a double ring, for example a bridged or spiro ring.

As used herein, the term "C₁-C₈Alkoxy "means a straight or branched chain alkoxy group having 1 to 8 carbon atoms; for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy and the like.

As used herein, the term "3-10 membered heterocycloalkyl having 1-3 heteroatoms selected from the group consisting of N, S and O" refers to a saturated or partially saturated cyclic group having 3-10 atoms and wherein 1-3 atoms are heteroatoms selected from the group consisting of N, S and O. It may be monocyclic or may be in the form of a double ring, for example a bridged or spiro ring. Specific examples may be oxetane, azetidine, tetrahydro-2H-pyranyl, piperidinyl, tetrahydrofuranyl, morpholinyl, pyrrolidinyl, and the like.

As used herein, the term "C₆-C₁₀Aryl "means an aryl group having 6 to 10 carbon atoms, for example, phenyl or naphthyl and the like.

As used herein, the term "5-10 membered heteroaryl having 1-3 heteroatoms selected from the group consisting of N, S and O" refers to a cyclic aromatic group having 5-10 atoms and wherein 1-3 atoms are heteroatoms selected from the group consisting of N, S and O. It may be a single ring or a condensed ring form. Specific examples may be pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1,2,3) -triazolyl and (1,2,4) -triazolyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl and the like.

Unless otherwise specified, the groups of the present invention may be substituted with a substituent selected from the group consisting of: halogen, nitrile group, nitro group, hydroxyl group, amino group, C₁-C₆Alkyl-amino, C₁-C₆Alkyl radical, C₂-C₆Alkenyl radical, C₂-C₆Alkynyl, C₁-C₆Alkoxy, halo C₁-C₆Alkyl, halo C₂-C₆Alkenyl, halo C₂-C₆Alkynyl, halo C₁-C₆Alkoxy, allyl, benzyl, C₆-C₁₂Aryl radical, C₁-C₆alkoxy-C₁-C₆Alkyl radical, C₁-C₆Alkoxy-carbonyl, phenoxycarbonyl, C₂-C₆Alkynyl-carbonyl, C₂-C₆Alkenyl-carbonyl, C₃-C₆Cycloalkyl-carbonyl, C₁-C₆Alkyl-sulfonyl, and the like.

As used herein, "halogen" or "halogen atom" refers to F, Cl, Br, and I. More preferably, the halogen or halogen atom is selected from F, Cl and Br. "halogenated" means substituted with an atom selected from F, Cl, Br, and I.

Unless otherwise specified, the structural formulae depicted herein are intended to include all isomeric forms (e.g., enantiomers, diastereomers and geometric isomers (or conformational isomers)): for example, R, S configuration containing an asymmetric center, (Z), (E) isomers of double bonds, and the like. Thus, individual stereochemical isomers of the compounds of the present invention or mixtures of enantiomers, diastereomers or geometric isomers (or conformers) thereof are within the scope of the present invention.

As used herein, the term "tautomer" means that structural isomers having different energies may exceed the low energy barrier, thereby converting with each other. For example, proton tautomers (i.e., proton transmutations) include interconversion by proton shift, such as 1H-indazoles and 2H-indazoles. Valence tautomers include interconversion by recombination of some of the bonding electrons.

As used herein, the term "solvate" refers to a complex of a compound of the present invention coordinated to solvent molecules in a specific ratio.

A compound of formula I

The invention provides a compound shown as the following formula I:

wherein,

R¹、R³each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6 alkyl;

R²selected from the group consisting of: H. halogen, CN, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy;

R⁶selected from the group consisting of: H. substituted or unsubstituted C1-C6 alkyl, R⁷-C(＝O)-、R⁸-S(＝O)₂-、R⁹R¹⁰N-C(＝O)-、R¹¹R¹²N-S(＝O)₂-a substituted or unsubstituted 5-12 membered heterocyclic group (including monocyclic, spiro, bridged or fused ring) having 1-3 heteroatoms selected from group N, S and O;

In another preferred embodiment, X¹、X²、X³、X⁴、R¹、R²、R³、R⁴、R⁵And R⁶Each independently is the corresponding group of the compounds of the examples.

In another preferred embodiment, the compounds of formula I of the present invention are the compounds prepared in the examples.

The compounds of the invention may be useful as JAK kinase inhibitors, in preferred embodiments, are JAK kinase selective inhibitors, for example, selective inhibition of one or more of JAK1, JAK2, JAK3 or Tyk 2. In a preferred embodiment of the invention, the JAK inhibitor selectively inhibits JAK 1.

Preparation of Compounds of formula I

The compounds of formula I of the present invention may be prepared by the following process:

pharmaceutical compositions and methods of administration

The compound of the present invention and various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates thereof, and pharmaceutical compositions containing the compound of the present invention as a main active ingredient are useful for the prevention and/or treatment of diseases (e.g., cancer) associated with the activity or expression level of JAK kinase, because the compound of the present invention has excellent inhibitory activity against JAK kinase.

The pharmaceutical compositions of the present invention comprise a safe and effective amount of a compound of the present invention in combination with a pharmaceutically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000mg of a compound of the invention per dose, more preferably, 10-200mg of a compound of the invention per dose. Preferably, said "dose" is a capsule or tablet.

"pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. By "compatible" is meant herein that the components of the composition are capable of intermixing with and with the compounds of the present invention without significantly diminishing the efficacy of the compounds. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), and the like

) Wetting agent (such as sodium lauryl sulfate), colorant, flavoring agent, stabilizer, antioxidant, antiseptic, pyrogen-free waterAnd the like.

The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, parenteral (intravenous, intramuscular or subcutaneous).

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, for example, glycerol; (d) disintegrating agents, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents, such as paraffin; (f) absorption accelerators, e.g., quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glycerol monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.

Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shells such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be delayed in release in a certain part of the digestive tract. Examples of embedding components which can be used are polymeric substances and wax-like substances. If desired, the active compound may also be in microencapsulated form with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly employed in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, in particular, cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of such materials and the like.

In addition to these inert diluents, the compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances, and the like.

Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols and suitable mixtures thereof.

The compounds of the present invention may be administered alone or in combination with other pharmaceutically acceptable compounds.

When administered in combination, the pharmaceutical composition further comprises one or more other pharmaceutically acceptable compounds. One or more of the other pharmaceutically acceptable compounds may be administered simultaneously, separately or sequentially with a compound of the invention.

When the pharmaceutical composition is used, a safe and effective amount of the compound of the present invention is suitable for mammals (such as human beings) to be treated, wherein the administration dose is a pharmaceutically-considered effective administration dose, and for a human body with a weight of 60kg, the daily administration dose is usually 1 to 2000mg, preferably 20 to 500 mg. Of course, the particular dosage will depend upon such factors as the route of administration, the health of the patient, and the like, and is within the skill of the skilled practitioner.

The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out under conventional conditions or conditions recommended by the manufacturers. Unless otherwise indicated, percentages and parts are by weight.

Example 1: (R) -N- (3- (2- ((3-methoxy-1-methyl-1H-pyrazol-4-yl) amino) pyrimidin-4-yl) - 1H-pyrrolo [2,3-c]Pyridin-7-yl) -2- (4-methylpiperazin-1-yl) propanamide

Example 1-2-chloro-1-toluenesulfonyl-1H-pyrrolo [2,3-c ]]Pyridine compound

Sodium hydrogen (375 mg, 9.37 mmol) was added portionwise to a solution of compound 1-1(950 mg, 6.25 mmol) in DMF (15 ml) under ice-water bath conditions and stirred for 20 min. Then p-toluenesulfonyl chloride (1.42 g, 9.37 mmol) was added in portions to this solution and stirred at room temperature for 4 hours. TLC and LCMS monitored the reaction, 1-1 disappeared, quenched with 100 mL water, extracted three times with ethyl acetate (50mL x 3), combined organic phases dried over anhydrous sodium sulfate and concentrated to give the product (1.45 g, 76% yield). MS (ESI) 307[ M + H ]]⁺.

Examples 1-3 7-chloro-3- (4,4,5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1-toluenesulfonyl- 1H-pyrrolo [2,3-c]Pyridine compound

Under the protection of nitrogen, compound 1-2(1.01 g, 3.6 mmol), pinacolborane (1 g, 7.2 mmol), [ Ir (COD) Cl]A solution of 2(120 mg, 0.18 mmol), 4,4 '-di-tert-butyl-2, 2' -bipyridine (96 mg, 0.38 mmol) and triethylamine (727 mg, 7.2 mmol) in tetrahydrofuran (50 ml) was stirred at 80 ℃ for 3 hours. LCMS monitors the reaction, after the reaction is complete, the solution is directly concentrated and purified by column chromatography (petroleum ether:ethyl acetate/10: 1-8:1) gave 980 mg of product as a yellow solid in 63% yield. MS (ESI) M/z 433[ M + H ]]⁺.

Examples 1-4-chloro-3- (2-chloropyrimidin-4-yl) -1-toluenesulfonyl-1H-pyrrolo [2,3-c ]]Pyridine compound

A solution of compounds 1-3(880 mg, 2 mmol), 2, 4-dichloropyrimidine (301 mg, 2 mmol), Pd (dppf) Cl2(146 mg,0.2 mmol) and potassium carbonate (552 mg, 4mmol) in 1, 4-dioxane (50 mL) was stirred at 100 ℃ overnight under nitrogen. After the reaction was completed, the solution was concentrated to dryness, and column chromatography (petroleum ether: ethyl acetate/5: 1) was carried out to obtain 260 mg of a product with a yield of 30%. MS (ESI) M/z 419[ M + H ]]⁺.

Examples 1-5- (7-chloro-1-toluenesulfonyl-1H-pyrrolo [2, 3-c)]Pyridin-3-yl) -N- (3-methoxy- 1-methyl-1H-pyrazol-4-yl) pyrimidin-2-amine

A dioxane solution (15 ml) of compound 1-4(230 mg, 0.55 mmol), 3-methoxy-1-methyl-1H-pyrazol-4-amine (84 mg, 0.66 mmol) and p-methyl toluene sulfonic acid (10 mg) was stirred at 100 degrees overnight. After the reaction was completed, it was neutralized with saturated sodium bicarbonate solution, extracted with ethyl acetate (30 ml), dried over anhydrous sodium sulfate, concentrated, and purified by TLC plate to obtain the product (20 mg, yield 10%). 1H NMR (400MHz, CD3OD-d4): δ (ppm)8.41(s,2H),8.20(d, J ═ 5.6Hz,1H),8.00(d, J ═ 4.8Hz,1H),7.67(s,1H),7.20(d, J ═ 5.2Hz,1H),4.03(s,3H),3.78(s,3H), MS-ESI: M/z 356[ M + H ] +.

Examples 1 to 7 methyl (R) -2- (4-methylpiperazin-1-yl) propionate

In IIIIn a neck flask (250 ml) dichloromethane (50 ml) and methyl (S) -2-hydroxypropionate (3 g, 28.8 mmol), 2, 6-lutidine (3.7 ml, 31.7 mmol) were added, under nitrogen, and the temperature was reduced to-78 ℃. Trifluoromethanesulfonic anhydride (5.36 ml g,31.7 mmol) was then added slowly at this temperature. The reaction was carried out at this temperature for 30 minutes and then allowed to warm to room temperature for one hour. The organic phase is washed twice with 1N aqueous hydrochloric acid, dried over sodium sulfate and concentrated to dryness. The resulting oil was dissolved with dichloromethane (50 ml), cooled to 0 ℃, and then 1-methylpiperazine (6.5 g, 64.6 mmol) was slowly added to the system, and potassium carbonate (21.2 g, 153.7 mmol) was added to the system at 0 ℃, followed by reaction at room temperature overnight. The reaction was washed with brine, dried and concentrated to dryness to give 5.7 g of a yellow oil. MS (ESI) M/z 187[ M + H ]]⁺.

Examples 1 to 8 (R) -2- (4-methylpiperazin-1-yl) propionamide

To an autoclave (100 ml) were added a methanolic ammonia solution (7N,46 ml), compounds 1-7(3.0 g, 16.1 mmol), heated to 150 ℃ and stirred for 48 hours. The reaction was directly concentrated to dryness to prepare a purified product as a white solid (480 mg, yield 17%).¹HNMR(400MHz,MeOD):δ(ppm)3.022-2.970(m,1H),2.607-2.442(m,8H),2.276(s,3H),1.231(d,J＝3.6Hz,3H)。MS(ESI):m/z＝172[M+H]⁺.

Examples 1 to 9: (R) -N- (3- (2- ((3-methoxy-1-methyl-1H-pyrazol-4-yl) amino) pyrimidin-4-yl) -1H-pyrrolo [2,3-c ] pyridin-7-yl) -2- (4-methylpiperazin-1-yl) propionamide

To a solution of (R) -2- (4-methylpiperazin-1-yl) propionamide (36mg,0.21mmol), (R) -2- (4-methylpiperazin-1-yl) propionamide (36mg,0.21mmol) and cesium carbonate (69mg,0.21mmol) in dioxane (1mL) was added palladium bis (dibenzylideneacetone) (13mg,0.014mmol), 4, 5-bis (diphenylphosphino) -9, 9-dimethylxanthene (16mg,0.028mmol), and the reaction solution was heated to 100C and stirred overnight. The desired product (R) -N- (3- (2- ((3-methoxy-1-methyl-1H-pyrazol-4-yl) amino) pyrimidin-4-yl) -1H-pyrrolo [2,3-c ] pyridin-7-yl) -2- (4-methylpiperazin-1-yl) propionamide (1.3mg, 3.8%) was obtained by preparative high performance liquid chromatography purification as a white solid. MS (ESI) M/z 491.7[ M + H ] +

1H NMR(400MHz,DMSO)δ11.53(s,1H),10.16(s,1H),8.33-8.23(m,2H),8.21(d,J＝5.3Hz,1H),7.90(s,1H),7.67(s,1H),7.11(d,J＝5.3Hz,1H),3.77(s,3H),3.68(s,3H),3.49(d,J＝7.0Hz,1H),2.64-2.50(m,4H),2.44-2.25(m,4H),2.15(s,3H),1.24(d,J＝7.0Hz,3H).

Example 2: n- (3- (2- ((3-methoxy-1-methyl-1H-pyrazol-4-yl) amino) -5-methylpyrimidine-4-) 1H-pyrrolo [2,3-c ] yl]Pyridin-7-yl) -2- (4-methylpiperazin-1-yl) butanamide

Example 2-1-chloro-3- (2-chloro-5-methylpyrimidin-4-yl) -1-toluenesulfonyl-1H-pyrrolo [2, 3-c)]Pyridine (II) Pyridine (I)

To a mixed solution of tetrahydrofuran/water (15 ml/5 ml) were added examples 1-3(350 mg, 0.81 mmol), 2, 4-dichloro-5-methylpyrimidine (264 mg, 1.62 mmol), pd (dppf) Cl2(60 mg, 0.08 mmol) and sodium carbonate (168 mg, 1.22 mmol) in this order, and the mixture was stirred at 80 ℃ for 2 hours. LCMS showed reaction complete. The reaction solution was diluted with ethyl acetate and washed with water. The organic phase was dried over anhydrous sodium sulfate and concentrated to give a crude product. The crude silica gel obtained was chromatographed (petroleum ether: ethyl acetate: 5:1) to give a yellow solid (200 mg, 57% yield ms (esi): M/z 432[ M + H)]⁺.

Example 2-2: 4- (7-chloro-1H-pyrrolo [2, 3-c)]Pyridin-3-yl) -N- (3-methoxy-1-methyl-1H-pyri-dine Azol-4-yl) -5-methylpyrimidin-2-amine

From example 2-1(365 mg, 0.843 mmol) the pale yellow solid compound of example 2-2(25 mg, 8% yield) was obtained in a similar manner to example 1 ms (esi) with M/z 370[ M + H ]]⁺。1H NMR(400MHz,MeOD-d4):δ(ppm)8.25(s,1H),8.17(s,1H),8.13(s,1H),7.95(d,J＝5.6,1H),7.63(s,1H),3.89(s,3H),3.73(s,3H),2.39(s,3H).

Example 2: n- (3- (2- ((3-methoxy-1-methyl-1H-pyrazol-4-yl) amino) -5-methylpyrimidin-4-yl) -1H-pyrrolo [2,3-c ] pyridin-7-yl) -2- (4-methylpiperazin-1-yl) butanamide

From example 2-2(25 mg, 0.068 mmol) a white solid was obtained (7.8 mg, yield 22%) in a similar manner to example 1. MS (ESI) M/z 519[ M + H ]]⁺.1H NMR(400MHz,cd3od)δ8.16–8.10(m,2H),8.07(s,1H),7.89(d,J＝5.6Hz,1H),7.64(s,1H),3.88(s,3H),3.71(s,3H),3.25–3.20(m,1H),2.85–2.52(m,8H),2.37(s,3H),2.32(s,3H),1.96–1.79(m,2H),1.06(t,J＝7.4Hz,3H).

Example 3: (S) -N- (3- (2- ((3-methoxy-1-methyl-1H-pyrazol-4-yl) amino) -5-methylpyrimidine- 4-yl) -1H-pyrrolo [2,3-c]Pyridin-7-yl) -2- (4-methylpiperazin-1-yl) butanamide

The title compound was obtained according to the procedure of example 2, substituting the corresponding starting material.

MS(ESI):m/z＝519[M+H]⁺.1H NMR(400MHz,cd3od)δ8.17–8.09(m,2H),8.07(s,1H),7.89(d,J＝5.6Hz,1H),7.64(s,1H),3.88(s,3H),3.71(s,3H),3.24–3.20(m,1H),2.85–2.52(m,8H),2.37(s,3H),2.30(s,3H),1.96–1.78(m,2H),1.06(t,J＝7.4Hz,3H).

Example 4: (R) -N- (3- (2- ((3-methoxy-1-methyl-1H-pyrazol-4-yl) amino)) -5-methylpyrimidine- 4-yl) -1H-pyrrolo [2,3-c]Pyridin-7-yl) -2- (4-methylpiperazin-1-yl) butanamide

MS(ESI):m/z＝519[M+H]⁺.1H NMR(400MHz,cd3od)δ8.14–8.09(m,2H),8.06(s,1H),7.88(d,J＝5.7Hz,1H),7.63(s,1H),3.88(s,3H),3.70(s,3H),3.21(dd,J＝7.7,5.6Hz,1H),2.85–2.49(m,8H),2.36(s,3H),2.30(s,3H),1.95–1.80(m,2H),1.06(t,J＝7.4Hz,3H).

Biological test example 1Jak l, Jak2, Jak3 kinase in vitro Activity test

Experimental Material

Recombinant human JAK1 protein was purchased from Thermo Fisher. JAK2, JAK3 proteins were purchased from Carna Biosciences. HTRF kinEASE TKkit was purchased from Cisbio Bioassays. The BioTek microplate reader Synergy Neo 2 plate was used.

Experimental methods

Test compounds were diluted in 4-fold concentration gradient to a final concentration of 10 μ M to 0.04nM 10 concentrations, two replicate wells per concentration; the content of DMSO in the assay reaction was 1%.

JAK1 enzyme reaction:

0.5 ng/. mu.l JAK1 protein kinase, 1. mu.M TK Substrate-biotin polypeptide Substrate, 1.1. mu.M ATP, 1 × enzymetic buffer, 5mM MgCl₂，1mM MnCl₂1mM DTT, 2.5nM SEB. The assay plate was WhiteProxiplate 384-Plus plate (PerkinElmer) and reacted at room temperature for 60 min in a 10. mu.l reaction system.

JAK2 enzyme reaction:

0.001 ng/. mu.l JAK2 protein kinase, 1. mu.M TK Substrate-biotin polypeptide Substrate, 2.7. mu.M ATP, 1 × enzymetic buffer, 5mM MgCl₂1mM DTT. The assay plate was a White Proxiplate 384-Plus plate (PerkinElmer) and reacted at room temperature for 25 minutes in a 10. mu.l reaction system.

JAK3 enzyme reaction:

0.004ng/μl JAk3 protein kinase, 1. mu.M TK Substrate-biotin polypeptide Substrate, 0.75. mu.M ATP, 1 × enzymatic buffer, 5mM MgCl₂1mM DTT. The assay plate was a White Proxiplate 384-Plus plate (PerkinElmer) and reacted at room temperature for 25 minutes in a 10. mu.l reaction system.

Reaction detection:

add 10. mu.l of assay reagent to the reaction plate, containing SA-XL665 at a final concentration of 0.125. mu.M and 1 XTK-Antibody 5. mu.l, incubated overnight at room temperature, Synergy Neo 2 read plate.

Data analysis

The 665/620Ratio value was converted into a suppression Ratio (%) (Ratio) by the following equation_max-Ratio_test)/(Ratio_max-Ratio_min)×100％。Ratio_maxRatio as a positive control without test Compound_minRatio as a negative control without test compound and kinase_testThe values were measured for each concentration of different compounds. IC50(nM) data were obtained by 4-parameter curve fitting, as shown in Table 1.

TABLE 1

Compound	JAK 1	JAK 2	JAK 3
				Example 1	78.6	648.9	2058
Example 2	5.8	88.7	245.8
				Example 3	11.37	81.73	434.5
Example 4	3.36	29.48	167.3

Biological test example 2: cytological JAK-STAT luciferase reporter gene assay

293T cells expressing SIE and ISRE luciferase reporter cells were constructed from anecdotal. The specific cell experiment procedure was as follows:

1. 20000293T/SIE cells or 293T/ISRE cells were seeded in 384-well cell culture plates in a medium volume of 20 ul.

2. The plates were CO-incubated at 37 deg.C₂Incubate overnight in the incubator.

3. The 5x compounds were prepared by serial dilution of the compounds in DMSO (1: 4) and then the compound solutions were diluted in culture medium (1: 40). The final concentration is 0.2-50000 nM.

4. 5ul of compound was dispensed in duplicate into assay wells. The plates were incubated in a 37 ℃ CO2 incubator for 1 hour.

5. IL-6 and IFN α were diluted in culture medium, 5ul IL-6 was dispensed to 293T/SIE cells or 5ul IFNa was dispensed to 293T/ISRE cells in duplicate, IL-6 was at a final concentration of 5ng/ml, IFN α was at a final concentration of 1000U/ml, wells with DMSO and stimulation were used as positive controls, DMSO was used only as a negative control.

6. The plates were CO-incubated at 37 deg.C₂Incubate in incubator for 6 hours.

7. The plates and One-glo reagent were equilibrated to room temperature. 25ul of One-glo reagent was added to each well, incubated for 3 minutes and read in a microplate reader using luciferase settings for 0.5 seconds.

Biological test example 3: TF-1 cytology JAK1/2 Activity detection assay

We determined JAK1 and JAK2 cellular activities in the same cell line TF-1 cells to avoid any problems caused by differences in response between alternate cell types. In TF-1 cells, IL-6 stimulation leads to STAT3 phosphorylation primarily by involvement in JAK1, while EPO stimulates JAK 2-dependent phosphorylation STAT 5.

TF-1 cells were obtained from the American Type Culture Collection (ATCC). TF-1 cells were starved overnight in OptiMEM medium containing 0.5% bovine serum (FBS), 0.1mM non-essential amino acids (NEAA), 1mM sodium pyruvate, and 37 ℃ phenol red free. Compounds were serially diluted in DMSO and incubated with TF-1 cells for 20 minutes at 37 ℃ with a final cell density of 100,000 cells/well and a final DMSO concentration of 0.2%. Human recombinant cytokine IL-6(30ng/mL) or EPO (10U/mL) was then added to the plates containing TF-1 cells at the indicated final concentrations, and the compounds and plates were incubated for 30 minutes. Phosphorylation of STAT3(IL-6) or STAT5(EPO) was then measured in cell lysates using ELISA kits. Will IC₅₀Values were determined as the concentration of compound required to inhibit STAT phosphorylation by 50% as measured relative to the DMSO control.

Biological test example 4: ex vivo detection of mouse colon tissue pSTAT3

1. Dissected mice remove the intact colon and open the lumen longitudinally.

2. The feces were washed off with cold PBS 3X. Tissues were rinsed with 30% EtOH and washed 2 times with PBS.

3. Cutting into 0.5-1 cm segments. Fragments were distributed in 24-well plates (2/well), 500ul HBSS. The tissue is re-cut into very small pieces in each hole.

4. The tissue was pre-treated with compound for 15 minutes. IFNr (100ng/ml) was then added for 10 minutes of treatment.

5. RIPA lysis buffer (containing protease inhibitor and 1mM NaVO4) was added and the tissue was homogenized. The lysate was centrifuged at 12000rpm for 10 minutes at 4 ℃. The supernatant was used to detect protein concentration and for ELISA testing.

6. Protein samples were diluted 20-fold in RIPA lysis buffer and protein concentration was tested by BCA kit using 25 μ Ι of diluted sample.

7. Based on the protein concentration results, protein samples were diluted to 0.5ug/uL for p-STAT3 and 0.1ug/uL for Total STAT3 testing (Elisa kit testing p-STAT3 and Total STAT3 levels. #73000C & # 7305C).

Biological test example 5: oxazolone (oxazone) induced colon pSTAT3 assay in mice

Oxazolone (50 μ L, 1%, 1:1 ethanol/water) was injected rectally and the drug or control (0.5% carboxymethylcellulose) was administered orally 3 hours after administration. After 1 hour, by inhalation of CO₂Mice were euthanized and the colon was immediately removed. Colonic samples were homogenized in lysis buffer (50mM Tris pH 7.5,150mM NaCl, 5mM EDTA, protease inhibitor (Roche) and phosphatase inhibitor). The resulting tissue lysates were centrifuged to determine protein concentration (Bradford assay) and the samples were diluted in RIPA buffer (1:10) to-1 mg/mL total lysate protein. Elisa kit testing p-Stat3 and TotalStat3 levels (CST # 73000C)&#7305C)。

Biological test example 6: drug effect experiment of small molecule inhibitor in treatment of oxazolone-induced colitis

Mice were anesthetized (2% isoflurane inhalation) and oxazolone (150ul, 4%, 4: 1 acetone/olive oil) was applied to the shaved skin area between the scapulae. After seven days, animals were fasted overnight and then anesthetized (2-4% isoflurane inhalation). A3.5-F catheter filled with oxazolone (1%, 1:1 ethanol/water) or vehicle was inserted rectally about 4cm and injected with 50. mu.L. Mice were administered by gavage starting the day before intrarectal administration of oxazolone. Two days after intrarectal oxazolone challenge, drug efficacy was assessed by scoring by the calculated disease index (DAI).

Biological test example 7: pharmacokinetic experiment of small molecule inhibitor mouse in the invention

Single Intravenous (IV) and oral (PO) administration of test compounds to CD-1 mice, blood samples were collected at different time points, and LC-MS/MS measurement of subjects in plasma of miceThe concentration of the test substance and the relevant parameters are calculated. The method comprises the following specific steps: taking a required amount of a test sample, dissolving the test sample in 0.9% NaCl, and preparing a solution with a required concentration for intravenous or oral administration. Animals were aged about 6-8 weeks at the start of the dosing experiment. Blood sampling time of vein: 0.083h, 0.25h, 0.5h, 1h, 2h, 4h, 8h and 24h after administration. The blood sampling time is as follows: 0.25h, 0.5h, 1h, 2h, 4h, 8h and 24h after administration. Establishing a biological sample analysis method and a sample detection method. Calculating pharmacokinetic parameters, such as AUC, of blood concentration data at different time points by using Phoenix WinNonlin 7.0 software_(0-t)，AUC_(0-∞)，T_1/2，C_max，T_maxAnd MRT, etc.

The results show that the compounds of the invention have excellent pharmacokinetic properties.

Biological test example 8: pharmacokinetic experiment of small molecule inhibitor rat in the invention

Test compounds were administered to SD rats in a single Intravenous (IV) and oral (PO) administration, respectively, blood samples were collected at different time points, and the concentration of the test substance in rat plasma was determined by LC-MS/MS and the relevant parameters were calculated. The method comprises the following specific steps: taking a required amount of a test sample, dissolving the test sample in 0.9% NaCl, and preparing a solution with a required concentration for intravenous or oral administration. Animals were aged about 6-8 weeks at the start of the dosing experiment. Blood sampling time of vein: 0.083h, 0.25h, 0.5h, 1h, 2h, 4h, 8h and 24h after administration. The blood sampling time is as follows: 0.25h, 0.5h, 1h, 2h, 4h, 8h and 24h after administration. Establishing a biological sample analysis method and a sample detection method. Calculating pharmacokinetic parameters, such as AUC, of blood concentration data at different time points by using Phoenix WinNonlin 7.0 software_(0-t)，AUC_(0-∞)，T_1/2，C_max，T_maxAnd MRT, etc.

All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.

Claims

1. A compound of formula I:

wherein,

R⁷、R⁸、R⁹、R¹⁰、R¹¹、R¹²each independently selected from the group consisting of: H. substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C1-3A 5-12 membered heterocyclic group of a heteroatom selected from the group consisting of N, S and O;

2. The compound of claim 1, wherein the compound of formula I has a structure according to formula Ia or formula Ib:

3. The compound of claim 1, wherein the compound of formula I has a structure selected from the group consisting of:

4. the compound of claim 1, wherein said compound has the structure shown in formula II:

wherein,

5. A compound of claim 1 wherein R is^7a、R^8a、R^9a、R^10aSelected from the group consisting of: hydrogen, methyl;

6. The compound of claim 1, wherein the compound of formula I is selected from the group consisting of:

7. a pharmaceutical composition comprising (1) a compound of claim 1 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof; (2) a pharmaceutically acceptable carrier.

8. Use of a compound according to claim 1 or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition according to claim 7, for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of a disease associated with an activity or an expression level of a JAK kinase.

9. The use according to claim 8, wherein the disease is selected from the group consisting of: cancer, cardiovascular disease, inflammation, immunological disease, myeloproliferative disease, viral disease, metabolic disease, or organ transplantation.

10. A JAK inhibitor comprising a compound of claim 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.